PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

20 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

14 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

05 июн 2023 13:52:38 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

25 май 2023 16:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

18 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

15 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

04 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

27 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

24 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

03 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

30 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 

29 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

28 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

16 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

07 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

01 мар 2023 07:00:02 Источник Nasdaq GlobeNewswire

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

27 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

16 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

08 фев 2023 15:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

06 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire